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Abstract 
The allocation of scarce resources among competing health care priorities is a key objective in all 
jurisdictions, whether in low- and middle-income countries (LMICs) or high-income countries. This 
involves allocating resources to ensure access to health care programmes, which can deliver 
improvements in health, but also to managing innovation in the development of new technologies, 
and investing in evidence generation activities to improve health for future generations. The 
allocation of health care resources among competing priorities requires an assessment of the 
expected health effects and costs of investing resources in the different activities and the 
opportunity costs of these expenditures, as well as an assessment of the uncertainty in health 
effects and costs. Uncertainty can lead to unintended adverse health consequences, e.g., when 
expected benefits of an activity are not realised when implemented in practice, or resources 
committed by an activity are transferred away from other health improving activities.  
 
The consequences of uncertainty can be reduced by investing in evidence generation activities that 
improve the information available to support future resource allocation decisions. An analytic 
framework is developed to assess the value of evidence generation activities to support 
international research funders, who have the responsibility for allocating funds among competing 
research priorities in Global Health. Within the framework, the costs and health benefits of evidence 
generation activities are assessed using the same principles as those employed when evaluating the 
cost-effectiveness of investments in service provision. Metrics of value, founded on an 
understanding of the health opportunity costs imposed by research expenditure, are used to 
quantify the scale of the potential global net health impact across all beneficiary populations (in net 
disability-adjusted life years averted), or the equivalent health care system resources required to 
deliver this net health impact, and research costs and their potential health opportunity costs. 
 
The framework can be applied to answer key questions such as: whether investment in research 
activities is worthwhile; which research activities should be prioritised; what type of research activity 
is necessary and what is the most appropriate design of the research; what are the opportunity costs 
associated with evidence generation; what is the optimal timing of research; and whether evidence 
generation activities should be prioritised over investments in service provision or new technology 
development. An illustrative example is used to demonstrate the application of the framework for 
informing research priorities in Global Health. 
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1. Introduction 
Health care decision-makers in all jurisdictions, whether in low- and middle-income countries 
(LMICs) or high-income countries, face difficult decisions when allocating resources to achieve 
agreed social objectives. At the highest level, resource allocation decisions are made across different 
sectors of the economy, e.g., level of spending on health care, education, security and defence, each 
of which have competing multiple objectives. An important social objective of health care 
expenditure is to ensure that overall health is improved for the population served. This involves 
ensuring access to health care interventions, or programmes, which can deliver improvements in 
health, whilst also managing innovation in the development of new health technologies to improve 
health for future generations. The challenge for health care decision-makers is to determine how 
best to allocate limited health care resources among numerous competing priorities. 
 
The allocation of health care resources among competing priorities requires an assessment of the 
expected costs and health effects of investing resources in individual health technologies (e.g., 
drugs, diagnostics, medical devices), health care programmes (e.g., public health interventions, 
health-system strengthening activities) and the opportunity costs of these expenditures. An 
investment in these activities may be considered to represent value to the health system if it offers 
an improvement in health that is expected to exceed the health that is forgone elsewhere from 
diverting resources away from other activities in order to accommodate the additional costs of the 
investment (i.e., health opportunity costs). In other words, the activity is only expected to represent 
a cost-effective use of resources if it offers positive net health effect to the health system. This holds 
true in both health care systems where there is an explicit assessment of health opportunity costs 
that fall on health expenditure, e.g., through a cost-effectiveness threshold, and systems where 
there is an absence of firm budget constraints, but where opportunity costs manifest in terms of 
other forms of expenditure, e.g., there is an implicit mechanism for rationing as increases to health 
care expenditure require increased taxation or co-payments. 
 
The value of an activity in terms of its expected net health impact is based on the balance of 
evidence currently available. However, uncertainty in the health effects that will be delivered by a 
programme and its costs (and therefore health opportunity costs) is unavoidable. This means that 
resource allocation decisions are subject to uncertainty. Uncertainty can lead to unintended effects 
such as adverse health consequences to individuals, as expected benefits of an activity are not 
realised, and to the population, as the resources committed by the activity are transferred away 
from other activities.   
 
Internationally, a significant amount of resource and effort is expended on health-related research 
activities aimed at supporting improved health care decision making. In HIV, for example, an 
estimated US$17 billion was invested over the period 2000-2016 on biomedical HIV prevention 
research and development [1]. Much of this research funding is aimed at better understanding 
current epidemiological trends and service provision, and how this would be impacted by changes to 
health care investments. These evidence generation activities encompass a wide range of types of 
studies and may include clinical trials, surveillance, cost studies, morbidity surveys and 
implementation studies. By improving the information available to support investment decisions, 
these evidence generation activities have the potential to improve population health by reducing the 
level of uncertainty in the current evidence base. However, as evidence generation activities are 
associated with considerable cost, and research funders have constraints on their ability to expand 
their research budgets, this raises an important question:  
 
How should international research funders assess the value of evidence generation activities and 
prioritise between competing research studies and other calls on their resources? 
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This question is pertinent for a wide range of research funding organisations that must prioritise 
research proposals across diverse clinical areas, types of studies, geographies and target 
populations. Organisations responsible for this type of research resource allocation include the Bill 
and Melinda Gates Foundation [2], the UK Department for International Development [3], the 
European & Developing Countries Clinical Trials Partnership [4], the US National Institute for Health 
[5], and the Medical Research Council [6].   
 
In this report, a framework is presented for assessing the value of evidence generation activities to 
support international research funders, who have the responsibility for allocating funds among 
competing research priorities. Here the focus is on research proposals that are ear-marked for 
research funding, and expected to have an impact on human health within the next 10-20 years (as 
opposed to basic physiology research, for example, which is expected to have a long pathway to 
impact). 
 
Within the framework, the costs and benefits of evidence generation activities are assessed using 
the same principles as those employed when evaluating the cost-effectiveness of investments in 
service provision. This involves quantifying the population health benefits of research, and weighing 
these against the health opportunity costs imposed by research expenditure.  
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2. The ecosystem of evidence generation  
Investments in evidence generation activities may be made at the international, national and sub-
national level, and often these investment decisions imply a commitment of resources across the 
different levels. For example, a clinical trial may be funded by an international organisation, but 
require local resources in terms of staff-time, overheads, equipment and/or consumables. However, 
the value of evidence generation activities can only be realised among those populations who can 
benefit from the improved decisions that result from the new information. An essential first step in 
assessing the value of an evidence generation activity is to understand the nature of the decisions 
that it could influence (e.g. a choice between different strategies for HIV outreach testing, or a 
choice between different packages of prevention care) and the populations whose health could be 
influenced, which may vary in terms of their size, geographical distribution and other characteristics, 
e.g., membership of high-risk subgroups.  
 
The value of generating evidence is likely to vary substantively in different populations, and the total 
value of the evidence generation activity can only be established by estimating the local net health 
effect of research and aggregating the local effects across all beneficiary populations (this is termed 
the global net health effect of research). The breadth of influence of the evidence generation 
activity, and therefore its value, will also depend on the extent to which the evidence generated in a 
specific population is considered generalizable across different geographies or different sub-
populations defined by disease, behavioural or other characteristics. As information generated by 
publically funded research is a public good, the health benefits from a local evidence generation 
effort may be realised over a much broader population, which can substantially increase the value of 
the research. In some circumstances, an evidence generation activity may offer the potential to 
inform multiple decisions. For example, improved surveillance data may inform investment decisions 
across a range of prevention and treatment decisions. The principles outlined in this report also 
apply to these wide-reaching evidence generation activities as value can be aggregated across the 
different decisions that will be informed by the research.  
 
The value of research also depends on the type of evidence generation activity. The health benefits 
derived from the evidence generation activity will depend on the nature of the study design and the 
degree to which it can reduce uncertainty, or reveal the sources of variation in outcomes. Different 
types of study designs inform different quantities, which may be important for decision-making 
about investments in health care. For example, observational cohort studies or surveillance 
programmes are often used to understand disease progression and outcomes in the absence of 
intervention, randomised controlled trials (RCTs) and implementation studies are often used to gain 
an understanding of intervention effectiveness, while cost and morbidity data may be collected from 
routine data collection exercises or surveys. The value of different study designs will depend both on 
the breadth of decisions that they could influence and on the likelihood that they could modify 
decision-making in a way that has substantive implications for population health. Another important 
way in which evidence generation activities can improve health is by identifying observed 
characteristics that explain variations in costs or health outcomes, such as epidemiological 
conditions or disease severity, including surveys aimed at better characterising variation in HIV 
prevalence across geographies or risk groups. This allows the population to be divided into finer 
subgroups, based on geography, risk-group or other observed characteristics. This can generate net 
health effect by allowing interventions to be focused only in those populations in which they deliver 
the greatest value. Table 1 provides examples of the types of evidence generation activities that are 
used to support decision-making for HIV treatment and prevention programmes in sub-Saharan 
Africa.  
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Table 1: Examples of evidence generation activities that support decision-making for HIV treatment and prevention programmes in sub-Saharan Africa  
Types of studies Key outputs used to inform decision making Example funders 
Phase I-IV clinical trials of medical 
interventions (drugs, diagnostics, 
vaccines) 
x Effectiveness, e.g., in terms of individual health outcomes or 
acquisition of HIV; 
x Measures of feasibility and cost of service implementation; 
x Formative work to inform potential epidemiological studies, 
implementation studies and trials. 
European & Developing Countries Clinical Trials Partnership 
(EDCTP) [4] 
UK Medical Research Council (MRC) [6] 
Wellcome Trust [7] 
US National Institutes of Health (NIH) [5] 
 
Implementation studies x Quasi experimental designs e.g., stepped wedge trials; 
x Impact of alternative models of delivery of care on programme 
engagement and costs in different populations and 
geographies. 
US NIH Fogarty International Center [8] 
Population Council [9] 
President's Emergency Plan for AIDS Relief (PEPFAR) [10] 
U.S. Agency for International Development (USAID) [11] 
Bill and Melinda Gates Foundation [2] 
Epidemiological studies (surveillance 
studies, and longitudinal follow-up) 
x Prevalence and incidence of HIV and their variation across 
time, place and subpopulations; 
x Behavioural surveillance measures (e.g. number and nature of 
sexual partners, use of condoms); 
x Programmatic data on number of individuals receiving specific 
treatments or prophylaxis; 
x Response to antiretroviral therapy (viral load, CD4 counts, 
resistance), rates of clinical events, including mortality, rate of 
loss to follow-up and re-engagement in care and how these 
vary across geographies and subpopulations. 
Nationally funded programme monitoring and surveillance data.   
USAID (funds Demographic and Health Surveys, DHS, alongside 
other international and national funders) [11] 
US Centers for Disease Control and Prevention (CDC) (funds 
Population-based HIV Impact Assessments (PHIA) surveys) [12] 
UK MRC [6] 
UK Department for International Development [3] 
Wellcome Trust [7] 
Bill and Melinda Gates Foundation [2] 
 
Cost studies x Programme costs and how these vary across geographies, by 
subpopulation, by programme scale and by service delivery 
modalities. May be integrated into trials or implementation 
studies; 
x Costs of long-term disease management.  
 
Bill and Melinda Gates Foundation [2] 
 
Morbidity surveys x Disability weights (for computation of disability-adjusted life 
years, DALYs). 
Bill and Melinda Gates Foundation [2] 
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Investment decisions relating to evidence generation activities will determine how the evidence 
base evolves over time and its benefits in terms of delivering population net health gains. Decisions 
regarding investment in evidence generation activities include:  
 
Prioritising investments from within a research budget:  
 
x Identifying research priorities across topics and programmes competing for funding; 
x Informing the type of research necessary and the design of the research; 
x Informing the timing of research, particularly when additional information that could 
influence decision-making is expected to become available in the short run; and 
x Determining how to allocate a high-level research budget across different funding streams 
(which may be demarked by types of studies, disease areas, geographical areas or settings). 
 
Accounting for the interaction between research and service provision choices: 
 
x Determining whether an evidence generation activity that would delay routine service 
implementation is worthwhile. 
 
Prioritising between research and other health-generating activities:  
 
x Determining how to allocate health care resources between research, provision of health 
care, and investment in the development of new technologies.  
 
These decisions influence the direction of significant global health resources, which impact on 
population morbidity and longevity. Quantifying the health implications of alternative uses of 
research resources, therefore, represents an important tool to inform transparent and accountable 
decision-making. The remainder of this report focuses on how the trade-offs implicit in resource 
allocation decisions about research priorities can be informed by robust quantitative analysis.  
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3. Metrics of value for informing research priorities 
The value of an investment in research can be assessed by comparing the expected health 
consequences of uncertainty, with and without the additional information, at the appropriate 
population level, to the health opportunity costs of acquiring the new information. The opportunity 
costs associated with research expenditure is the value of the activities that are displaced elsewhere 
to accommodate the costs of research. Insofar as there is funding dedicated to research activities, 
the opportunity costs incurred by the research funder is the funding (and associated health benefits) 
that are diverted away from other types of research competing for the same resources. The cost 
associated with implementing the research at a local level also incurs opportunity costs. These 
opportunity costs are different from those incurred by the research funder because the costs are 
incurred on the ground by the local health care system. The opportunity cost at a local level is the 
diversion of resources away from service provision, or other types of locally relevant research, which 
falls on the local health care budget.   
 
In this report, both health and health opportunity costs are represented in terms of disability-
adjusted life years (DALYs). Analyses informing resource allocation decisions in LMICs have most 
commonly used DALYs as a measure of the effect of alternative programmatic choices on morbidity 
and mortality [13] and this measure of health is generally preferred by international donors such as 
the World Health Organisation [14] and World Bank [15]. Nonetheless, the approaches presented in 
this report apply equally to other measures of health, such as the quality-adjusted life year (QALY).  
 
The health opportunity costs of expenditures incurred by local health care systems will vary across 
settings, with estimates of these opportunity costs now available for most low, middle and high 
income countries [16 W18]. The health opportunity costs of dedicated international research funds 
are expected to vary substantively across funders according to their specific focus, and whether the 
budgets held for research are potentially fungible between research and other activities. It is, 
therefore, essential that any metrics representing the value of investments in evidence generation 
activities separate out these different types of costs to allow the different opportunity costs to be 
considered in the research prioritisation process.  
 
Three metrics are proposed when appraising the value of an evidence generation activity: (i) the 
global net health effect across all benefiting local populations, which takes into account health 
opportunity costs incurred locally; (ii) the equivalent health care system resources required to deliver 
the health effects; and (iii) the research costs and their potential health opportunity costs.  
 
Funding decisions may also be informed by the distribution of the benefits of research, which 
depends on the mandate and priorities of the research funder. For example, in some contexts DALYs 
averted in very low income settings where the burden of disease is very high may be given a higher 
weight, but in other contexts, research may be funded where the burden of disease is lower, e.g., if 
the DALYs averted by research vastly exceed those that could be generated by directly funding 
services within the local health care system. Therefore, it is recommended that an estimate of the 
global net health effect is presented, alongside an estimate of the net health effect disaggregated by 
specific country, risk group or other grouping that is considered important by the research funder 
(e.g., country income category, Global Alliance for Vaccines and Immunisations (GAVI) eligible, 
vulnerable or priority populations, or recipient household income). 
 
3.1 Assessment of the global net health effect  
DALYs averted by research at a local level are illustrated in Table 2 for an evidence generation 
activity, which is expected to influence decisions for two distinct subpopulations in two countries.  
The countries are only expected to differ in the opportunity costs of local health care expenditure. 
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For example, for country 1, the assessment of health opportunity costs is $200 per DALY averted, 
reflecting the amount of resource required to deliver one DALY averted in that health care system, 
while for country 2 the corresponding value is $500 per DALY averted. The stratification of 
subpopulations within these countries is used to reflect the fact that research is likely to offer 
different value in different subpopulations and may be used to target services to a particular 
subpopulation.   
 
The health benefits of research in each subpopulation are presented in column A as the number of 
DALYs averted by resolving the existing levels of decision uncertainty about the quantity under 
evaluation. The corresponding local health expenditure that would be required to achieve this health 
improvement via service provision is given in column B, by multiplying the DALYs averted in column 
ďǇƚŚĞĐŽƵŶƚƌǇ ?ƐĞƐƚŝŵĂƚĞĚ local health opportunity costs. The costs of research that fall on the 
local health care system, e.g., costs associated with implementing the research at a local level, are 
presented in column C. The corresponding health opportunity costs of the research, expressed in 
terms of DALYs averted, are presented in column D  ?ƌĞƐĞĂƌĐŚĐŽƐƚƐĚŝǀŝĚĞĚďǇƚŚĞĐŽƵŶƚƌǇ ?ƐĞƐƚŝŵĂƚĞ
of local health opportunity costs). The net health effect in each subpopulation is presented in 
column E, expressed as net DALYs averted (i.e., the difference between column A and D). The 
corresponding health expenditure required within the local health care service to achieve the net 
health effect is presented in column F  ?ŝ ?Ğ ? ?ĐŽůƵŵŶŵƵůƚŝƉůŝĞĚďǇƚŚĞĐŽƵŶƚƌǇ ?ƐĞƐƚŝŵĂƚĞŽĨůŽĐĂů
health opportunity costs).   
 
If the local net health effect of research is positive (for example, subpopulation 1 in country 1 and 
country 2), then further evidence generation is potentially a cost-effective use of health care 
resources in that setting. In subpopulation 2 of country 2, the expected health benefits of research, 
equivalent to 30 DALYs averted, are the same as the health opportunity costs associated with the 
research expenditure at the local level. Therefore, in this setting, research will neither improve nor 
reduce health outcomes (i.e., the net DALYs averted are zero). In subpopulation 2 of country 1, the 
health opportunity costs associated with local research expenditure exceed the health benefits of 
research; therefore, research is expected to reduce health outcomes (i.e., the net DALYs are 
negative). In other words, the opportunity cost at a local level through the diversion of resources 
away from service provision or other types of locally relevant research is greater than the health 
expected to be gained from the research in subpopulation 2 of country 1. The global net health 
effect is estimated as the total net DALYs averted across the subpopulations (i.e., 1,025 net DALYs 
averted).   
 
Table 2: The net value of research in different settings 
  Health benefits of 
research* 
Costs of research at local 
level 
Net value of research 
Country Sub- 
population 
DALYs 
averted** 
(DALYS) 
 
[A] 
Equivalent 
health care 
expenditure 
(,000 $) 
[B] 
Research 
costs 
(,000 $) 
 
[C] 
Health 
opportunity 
costs 
(DALYs) 
[D] 
Net 
DALYs 
averted 
(DALYS) 
[E] 
Equivalent 
health care 
expenditure 
(,000 $) 
[F] 
1ゆ 1 100 20 5 25 75 15 
2 20 4 10 50 -30 -6 
2ょ 1 1,000 500 10 20 980 490 
2 30 15 15 30 0 0 
Total across subpopulations (global values) 1,025 499 
 ? The assessment of local health opportunity costs is $200 per DALY averted in country 1; 
 ? The assessment of local health opportunity costs is $500 per DALY averted in country 2; 
* For simplicity, no time horizon for research is considered here; it implicitly assumes that research reports immediately 
and the costs of research are incurred immediately  W this assumption is revisited later in the report; 
** DALYs expected to be averted as a result of the research giving greater certainty about the quantities of interest. 
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3.2 Comparison of the net health effect of research with the opportunity costs of 
research funding 
If an evidence generation activity offers a positive global net health effect, while taking into account 
local research costs, then the research is potentially worthwhile. However, for the research to be 
considered net health improving the opportunity costs of the research funds also need to be taken 
into account. One way to consider this is to directly compare the global net health effect (e.g., global 
net DALYs averted) per research $ across research topics competing for the same resources. If the 
ƌĞƐĞĂƌĐŚĨƵŶĚĞƌ ?ƐŽďũĞĐƚŝǀĞŝƐƚŽĂǀĞƌƚƚŚĞŵŽƐƚ>zƐ ?ĂŶĚĂ>zĂǀĞƌƚĞĚŝƐĐŽŶƐŝĚĞƌĞĚƚŚĞƐĂŵĞ
across jurisdictions and populations), a cost per DALY league table of all research proposals may be 
used to indicate the relative priority of the research topics. In this way, the global research funder 
works down the ordered list, funding all proposals until the research resources run out.   
 
The cost per DALY averted of the last funded proposal implies a value for health opportunity costs of 
global research funds. The relative value of the opportunity costs of research compared to other 
uses of health care resources, such as service provision, can start to indicate whether the research 
budget is low, sufficient or whether research funds should be directed towards service provision or 
other activities instead. For example, if the cost per DALY averted for the research budget is higher 
than the health opportunity cost thresholds used for service provision in the countries that benefit 
from the research, this indicates that overall health may be improved by transferring research 
funding to direct service provision instead of research.  
 
A second way to consider the potential opportunity costs of research funds is to assess whether the 
global cost per net DALY averted is lower than the cost of averting DALYs in the country or health 
care system with the lowest cost per DALY threshold, i.e., whether research improves overall health 
to a greater extent than investments in service provision. For the example in Table 2, if the research 
costs were $1 million this would generate 5,000 DALYs in country 1 (i.e., $1 million divided by the 
ĐŽƵŶƚƌǇ ?ƐĞƐƚŝŵĂƚĞŽĨůŽĐĂůŚĞĂůƚŚŽƉƉŽƌƚƵŶŝƚǇĐŽƐƚƐŽĨ ? ? ? ?ƉĞƌ>zĂǀĞƌted), which is much 
greater than the global net DALYs averted by the research (i.e., 1,025 DALYs), suggesting that the 
research may not be worthwhile compared to other potential uses of the research funds (assuming 
that there is flexibility to use the funds outside of research). A third approach is to compare the 
health care expenditure that would be required to avert the same number of DALYs within service 
provision with the costs of research. Again, if the research costs were $1 million this would appear 
high compared to the $499,000 required to generate the same amount of health via direct service 
provision in Table 2, suggesting that research may not be a cost-effective option.  
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4. Methods for estimating the health benefits of further evidence generation 
activities 
Underpinning the metrics of value for informing research priorities (Section 3) is an understanding of 
the local net health effect of evidence generation activities. This can be established using methods of 
Value of Information analysis [19,20], which quantifies the value of further research as the expected 
improvement in health that could be gained by reducing the consequences of uncertainty in the 
existing evidence base.  
 
4.1 Heuristic approach to the estimation of the value of research 
Once the decisions that will be informed by the research have been identified, it is necessary to 
understand the quantities that will be estimated from the evidence generation activity. For example, 
a RCT of an intervention will typically inform the magnitude of effect of the intervention on key 
clinical outcomes, which is often quantified as a relative treatment effect (e.g., an odds ratio for 
treatment response, or a hazard ratio for all-cause mortality). An observational study, such as a 
surveillance programme, might inform the prevalence of HIV in a series of geographical areas and/or 
risk groups. The expected value of perfect information for a single quantity or group of quantities 
(known as the Expected Value of Partial Perfect Information, EVPPI), can be used to provide an 
expected upper bound on the value of eliminating uncertainty in the existing evidence base for the 
particular quantity (or group of quantities). This is used to start to indicate whether the evidence 
generation activity is likely to be of value. 
 
In order to estimate the value of resolving uncertainty about a specific quantity, it is necessary to 
understand two key elements: (i) the current level of uncertainty in the quantity of interest; and (ii) 
the implications of this uncertainty for the net health effect of the choice between alternative 
interventions. Note that there is only value associated with reducing uncertainty for quantities that 
would change the health care decision.  
 
Uncertainty regarding the  ‘true ? value of a quantity of interest can be characterised by assigning a 
probability distribution to reflect the probability that the quantity may take a range of different 
values (see Figure 1, panel b). This may be informed by the available data relating to the quantity of 
interest such as small previous individual studies or a synthesis of evidence from previous studies 
[19]. For example, if the evidence generation activity is a surveillance programme, then there is likely 
to be some information from existing smaller surveys regarding HIV prevalence. This data will be 
available as a proportion, or number, of cases out of a total number of individuals surveyed, and its 
uncertainty can be represented by a beta distribution. Methods for selecting an appropriate 
distribution to represent uncertainty and quantify the available information (e.g., mean and 
confidence interval from existing studies) are reported in Briggs et al (2006) [19]. In some 
circumstances, there may be no available information on the quantity of interest. In this case, the 
value of the quantity and an estimate of its uncertainty may rely on expert opinion. Formal methods 
of expert elicitation may be used to elicit the views of experts and to quantify uncertainty in their 
beliefs [21,22].  
 
Once the uncertainty around the quantity of interest has been characterised as a distribution, it is 
possible to identify the probability that the quantity of interest will take a value that will result in a 
change in decision. Therefore, the second step required to estimate the value of resolving 
uncertainty about a specific quantity is to identify the value of the quantity beyond which the 
decision based on current information would switch to a different intervention choice, i.e., the 
 ‘ƚƌŝŐŐĞƌƉŽŝŶƚ ? in the quantity that switches the decision. If the trigger point is considered 
implausible, then further research will not result in a change in decision and, therefore, research 
should not be conducted.   
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A decision between alternative interventions would select the intervention with the highest 
expected (average) net health effect based on existing information. The trigger point represents the 
value for the quantity of interest at which this decision would switch and a different intervention 
would become the net health maximising choice. This is illustrated in Figure 1, panel a. At the mean 
ǀĂůƵĞŽĨƚŚĞƋƵĂŶƚŝƚǇŽĨŝŶƚĞƌĞƐƚ ?ƌĞƉƌĞƐĞŶƚŝŶŐƚŚĞ ‘ďĞƐƚŐƵĞƐƐ ?ŽĨǁŚĂƚƚŚĞquantity value might truly 
be) the intervention has a negative net health effect and is not considered to be cost-effective, i.e., 
the health opportunity costs of implementing the intervention are too great to justify the health 
benefits. However, beyond a certain trigger point the net health effect of the intervention becomes 
positive. The area to the right of the trigger point (Figure 1, panel b, shaded area) indicates the 
probability that the results of research would change the decision. The corresponding bars in Figure 
1, panel a, represent the potential health gains that could be accrued with the change in decision. 
The value of resolving uncertainty about the quantity is calculated as the health consequences of the 
quantity taking a value beyond the trigger point (i.e., the shaded bars in Figure 1, panel a), weighted 
by the probability of the quantity taking each value beyond the trigger point (i.e., the shaded area in 
Figure 1, panel b). 
 
If there are multiple interventions there may be multiple trigger points. For example, if the quantity 
of interest is HIV prevalence, the current assessment of prevalence might support a low-intensity 
prevention programme, whereas if HIV prevalence fell below a lower trigger point, the decision 
maximising the net health effect might switch to no prevention, and, if HIV prevalence fell above a 
higher trigger point, the decision might switch to a high intensity prevention programme. 
 
As well as an estimate of current uncertainties about the quantity of interest, the method outlined 
above requires an estimate of the (incremental) net health effect of each intervention conditional 
upon different values of the quantity of interest. This may be informed by an epidemiological or 
cost-effectiveness model that is able to provide estimates of costs and health outcomes for 
alternative interventions, or in the absence of a model via expert elicitation [21,22]. When a model is 
available, the simplest way to estimate net health effect is via one-way sensitivity analysis [19]. This 
ŝƐǀĞƌǇƐŝŵŝůĂƌƚŽƚŚĞ ‘ŽŶĞ-ůĞǀĞů ?ƐŝŵƵůĂtion approach to EVPPI proposed in the literature [23]; the 
only difference is that for the one-level approach, the model is re-run for a series of samples from 
the quantity distribution rather than formulating the distribution and the conditional net health 
effect curve separately and then combining them.   
 
The well-documented limitation of these approaches is that they use the mean values for the other 
quantities in the model when computing net health effect for different values of the quantity of 
interest [24]. This will produce biased estimates of the net health effect curve if the model is a non-
linear function of the other quantities in the model, or correlation between the quantity of interest 
and the other quantities within the model exists [24].  
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Figure 1: Estimating the value of resolving uncertainty about a quantity of interest 
 
A range of alternative methods have been developed to address this limitation. A number of these 
methods require evidential uncertainty to be quantified via a probabilistic sensitivity analysis (PSA) 
[19]. This involves specifying a probability distribution for each of the uncertain quantities and then 
propagating this uncertainty through the model using Monte Carlo simulation (i.e., drawing a value 
for each quantity from the specified distributions) to derive the uncertainty around intervention 
costs and effects, and the corresponding uncertainty around the net health maximising intervention 
[19]. The variation in the model output over all simulations reflects the impact of uncertainty in all of 
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SOC (DALYs)
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(b) Probability density function for uncertain quantity 
Quantity on which research will be 
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(a) Incremental net health benefit of  intervention for different values of  research quantity 
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the quantities simultaneously. This type of Monte Carlo simulation can be extended to estimate 
EVPPI by first sampling a value from the quantity of interest, holding that value fixed, and then 
sampling from the remaining quantities conditional on the value of the quantity held fixed; then 
repeating this sampling process many times to reflect the impact of uncertainty that is attributable 
to the specific quantity of interest (often known as two-level simulation) [19]. The two-level 
simulation approach is computationally very expensive and has been found to be infeasible for 
computationally expensive models. Methods have been developed to approximate the two-level 
simulation in order to reduce the associated computational challenges. Two broad approaches have 
been used: (i) replace the existing model with a meta-model and use the meta-model to generate 
estimates of uncertainty and value of information [25 W28]; and ii) use non-parametric regression 
methods to approximate EVPPI from the PSA samples [29,30]. However, all of these methods still 
require a PSA or sufficient simulations to develop a meta-model as a starting point, which may not 
be available for complex models in HIV. Although it may be feasible for many models, it is likely to be 
so computationally expensive as to be prohibitive for real-time policy decisions. Therefore, despite 
the limitations of the heuristic approach, this may represent the only feasible approach in some 
settings and circumstances. 
 
For some models, calibration is an important part of model parameterisation. Calibration refers to 
the process of estimating the parameters of the model so that model predictions are consistent with 
external data (e.g., data on key epidemiological trends), where the external data is often referred to 
as the calibration target [31]. Calibration is often used when some quantities in the model are 
difficult to estimate directly, and to ensure that models provide credible representation of all 
observed data. If Bayesian methods are used for calibration, then these can be used to generate PSA 
outputs, and subsequently used to generate EVPPI estimates [32].  Application of full Bayesian 
calibration methods may be infeasible. In these circumstances, application of a more restricted 
Bayesian calibration approach reflecting uncertainty only in those parameters likely to be most 
influenced by the calibration target(s) may be feasible. This could be used to provide revised 
parameter means for the remaining quantities not of direct interest, and may also provide an 
updated prior for the quantity of interest if this is included within the Bayesian calibration process.  
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5. Framework for assessing the value of evidence generation activities 
This section considers how the estimates of the value of reducing uncertainty about a specific 
quantity may be used to inform the overall assessment of the value of an evidence generation 
activity. Whether evidence generation activities deliver value at the local level depends upon the 
policy options available to decision makers, with and without the evidence generation activity, and 
how these policies could improve population health [33]. Without further evidence generation 
activities, ĚĞĐŝƐŝŽŶŵĂŬĞƌƐĐĂŶĞŝƚŚĞƌŝŵƉůĞŵĞŶƚĂŶŝŶƚĞƌǀĞŶƚŝŽŶ ? “ĂƉƉƌŽǀĞ ?ƉŽůŝĐǇ ?ŽƌƌĞƚĂŝŶƚŚĞ
ĐƵƌƌĞŶƚƐĞƌǀŝĐĞǁŝƚŚŽƵƚŝŵƉůĞŵĞŶƚŝŶŐĂŶŝŶƚĞƌǀĞŶƚŝŽŶ ? “ƌĞũ Đƚ ?ƉŽůŝĐǇ ? ?When there is uncertainty in 
costs and health effects and further evidence generation activities are needed to reduce uncertainty, 
two additional policy options are available. The evidence generation activities could be pursued 
alongside routine implementation of the intervention ( “approval with research ?, AWR policy). Under 
this policy choice, the decision maker can withdraw the intervention when the evidence generation 
activity reports, if continued provision does not appear cost-effective in light of the new evidence. 
Alternatively, the decision maker can hold back from routine implementation of the intervention 
whilst the evidence is being generated and then decide whether to implement the intervention once 
ƚŚĞŶĞǁĞǀŝĚĞŶĐĞŝƐĂǀĂŝůĂďůĞ ? “ŽŶůǇŝŶƌĞƐĞĂƌĐŚ ? ?K/Z policy). The potential incremental value of 
evidence generation activities will depend crucially on the extent to which the policy options that 
involve evidence generation activities (AWR, OIR) generate additional population health compared 
to those which do not (approve, reject).  
 
This section of the report sets out a framework for estimating the additional value of policies that 
involve evidence generation activities, in order to inform evidence-based decision making about 
investments in research. When assessing the value of evidence generation activities there are three 
key issues to consider: (i) Does research seem potentially worthwhile?; (ii) What kind of research 
would best support decision making?; and (iii) Are there additional opportunity costs associated with 
generating evidence? These considerations are described below and summarised in Box 1.  
 
Box 1: Considerations when assessing the value of evidence generation activities 
Theme Considerations 
Theme A: Does research 
seem potentially 
worthwhile? 
An understanding of how health care decisions could be influenced by the 
evidence generated. 
Identify quantities that contribute to decision uncertainty and on which further 
evidence could be obtained, type of evidence generation activities that could 
inform these quantities, and the value of reducing uncertainties. 
Consider future uncertainties that could impact on the value of evidence 
generation activities: price changes, entry of other technologies, and availability 
of ongoing research. 
Consider the degree to which uncertainty is expected to be resolved by the 
proposed evidence generation activities. 
Theme B: What kind of 
research would best 
support decision 
making? 
Consider value of study designs that provide information on different 
quantities: these will include studies looking at different sets of outcomes and 
in the case of comparative research studies, comparing different sets of 
interventions.   
Where multiple studies could be commissioned to inform a decision consider 
whether one study, multiple studies or a sequential approach should be 
pursued, and consider delaying research until other uncertainties resolve. 
Theme C: Are there 
additional opportunity 
costs associated with 
generating evidence? 
Consider whether research would require delayed implementation of cost-
effective services and the potential for this to reduce the added value of the 
evidence generation activity.  
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5.1 Theme A: Does research seem potentially worthwhile? 
This theme evaluates whether or not there is the potential for research to generate local and global 
net health gains, and whether or not these health gains might be considered sufficient to offset the 
health opportunity costs of the research expenditure. To understand the scale of the potential 
benefits of evidence generation activities, the number and nature of the decisions that could 
potentially be informed by further evidence generation activities needs to be understood. The scale 
of the population that could benefit from improved decision making is an important determinant of 
the value of research and requires consideration of the populations who are expected to benefit 
(Section 2) and whether the evidence is likely to be informative for decision making over a long time 
ĨƌĂŵĞŽƌĂƌĞůĂƚŝǀĞůǇƐŚŽƌƚ “ƐŚĞůĨ-ůŝĨĞ ?.  
 
Once the potential beneficiaries of improved evidence have been identified, it is necessary to 
understand which quantities are important drivers of decision uncertainty and the type of evidence 
generation activities that could reduce this uncertainty. If for all plausible estimates of a quantity, 
the decision would be the same, then that quantity is not an important driver of decision uncertainty 
and knowing more about that quantity would not change decisions and cannot, therefore, improve 
population health. However, if the cost-effective intervention choice does change at different 
plausible values of the quantity, then knowing more about that quantity has the potential to 
improve population health and may be a valuable target for evidence generation activities. 
 
Once these assessments have been made it is possible to estimate the expected maximum local 
value of an evidence generation activity. This requires knowledge about the likelihood that the 
uncertain quantity takes a range of values, and how those values could alter decision making and, 
therefore, population health, as shown in Section 4. The total potential value of conducting an 
evidence generation activity can be estimated by aggregating the local values of the evidence 
generation activity across those populations who will benefit from the information and comparing 
this to the opportunity costs imposed by the research expenditure (see Section 3).  
 
In some contexts, future changes that are uncertain and will only resolve over time may 
substantively modify the value of evidence generation activities. For example, even if the current 
benefits of research are considerable, if the price of the technology is likely to fall significantly before 
or shortly after the research reports, or if future innovation makes the current technology obsolete, 
then the future benefits once the research reports might be very limited. Therefore, the expected 
impact of future changes over time should be assessed. 
 
Finally, it is necessary to consider the extent to which the proposed evidence generation activity will 
reduce uncertainty about the quantity of interest. For example, a large and expensive study that 
provides a more definitive answer regarding the true value of the quantity of interest will represent 
quite a different value proposition compared to a small-scale relatively cheap study, which will 
increase our understanding of the quantity but still leave the decision maker with a substantive 
degree of residual uncertainty. The proposed study (e.g., RCT) may be designed to test the 
hypothesis that the true value of the quantity is greater than the trigger point that switches the 
decision. 
 
5.2 Theme B: What kind of research would best support decision making? 
Theme A may identify a series of quantities for which research is expected to be potentially 
worthwhile, and different studies that could support improved understanding of these quantities. 
This raises two questions: (i) how should individual studies be designed?; and (ii) how should 
research programmes involving multiple evidence generation activities be designed? 
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The design of any research study implies a large number of choices, which will have implications for 
the value of the evidence generation activity. The size of the study, and other factors which could 
influence its ability to resolve uncertainties about the quantity of interest, will have important 
implications for both its value and cost. The quantities which can be estimated by the study may also 
profoundly impact upon the value of the study. Different study designs may allow a comparison of 
different interventions and may provide data on different biochemical, care-related or economic 
endpoints. For example, in the context of outreach testing in HIV, two important uncertain 
quantities are the cost per HIV case identified and the likelihood that individuals newly identified as 
HIV positive will be linked to appropriate care [34 W37]. An appraisal of both a short, cheaper study, 
looking at the cost per HIV case identified and a longer more expensive study examining this 
outcome, as well as recording linkage rates, would allow the value of these alternative designs to be 
compared. This could potentially allow research funds to be used more effectively than if only one 
study design was considered. However, careful consideration must also be given to the 
generalisability of the findings from different studies; for example, studies examining the same 
outcome may vary significantly in terms of the characteristics of the specific setting, the outreach 
approach, and changes over time. The extent to which outcomes can be generalised across studies 
will depend, in part, on the outcome examined; for example, a study examining the intrinsic efficacy 
of a new intervention is less likely to vary across populations compared to studies examining 
outreach testing in HIV.  
 
Another important aspect of research design is the selection of intervention and comparator study 
arms in comparative research. For example, if decision makers are currently uncertain about 
whether a high or low intensity version of an intervention is cost-effective, then this comparison 
should be the focus of the comparative study, while a study comparing the high intensity 
intervention to a no intervention option may be of limited value. If there is uncertainty about which 
of the three interventions is cost-effective (high-, low- or no intervention) then a three-arm study 
may represent better value than a two-arm study. Again, assessing the value of alternative designs 
and their costs may allow for more effective use of research funds and enable the identification of 
high value evidence generation activities for targeted investment.  
 
In some contexts, multiple evidence generation activities may be valuable. For example, a trial 
focused on short-term outcomes and an observational study linking short-term clinical outcomes to 
long-term patient morbidity and mortality may appear valuable. In this case a decision maker has 
the option to commission one or both studies, commission one study and review its results prior to 
deciding whether to commission the seĐŽŶĚ ?Ă “ƐĞƋƵĞŶƚŝĂů ?ƌĞƐĞĂƌĐŚƉƌŽŐƌĂŵŵĞ ?, or simply waiting 
ƚŽĐŽŵŵŝƐƐŝŽŶŽŶĞŽƌďŽƚŚƐƚƵĚŝĞƐƵŶƚŝůŽƚŚĞƌƵŶĐĞƌƚĂŝŶƚŝĞƐĂƌĞƌĞƐŽůǀĞĚ ?Ă “ǁĂƚĐŚĨƵůǁĂŝƚŝŶŐ ?
approach). Assessing the value of alternative programmes of research again offers the potential to 
identify high value programmes at which to target research funds.  
 
5.3 Theme C: Are there additional opportunity costs associated with generating 
evidence?  
If research is considered valuable, then, in principle, the AWR policy can be pursued when the 
intervention is cost-effective and the OIR policy pursued when it is not. However, parallel service 
implementation and research (i.e. AWR) may be impractical for a number of reasons. Firstly, service 
implementation while research is underway could contaminate the findings of research. Secondly, it 
can raise ethical issues, and/or make recruitment into the research impracticable. Thirdly, it may not 
be politically appropriate or practical to withdraw the intervention after the research reports, even if 
the evidence generated does not support continued implementation (i.e. an AWR policy would 
actually be an approve decision but with added research costs). Therefore, there may be additional 
opportunity costs associated with implementing an evidence generation programme if it prohibits 
wide-scale implementation of the service while the research activity is conducted. If this is the case, 
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then the health implications associated with not implementing a cost-effective technology while 
research is underway needs to be accounted for when evaluating the evidence generation activity.  
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6. Illustrating the conceptual framework for the value of evidence generation 
activities 
A simple illustrative example is used to show how the framework can be applied to provide 
quantitative assessments of the value of evidence generation activities.  
 
6.1 Overview of illustrative example 
The illustrative example considers the decision about whether or not to provide an intervention 
which aims to prevent HIV infection. Only these two policy options are considered for illustrative 
purposes; in reality, the decision-maker may face a wider range of alternative options (e.g., in HIV 
where there may be a need to consider different combinations of interventions and different 
population coverage levels). Two countries are considering: a low income country (LIC) and a middle 
income country (MIC). Decision makers in each country face the decision about whether to provide 
the intervention in a low- and a high-risk subpopulation. A simple decision tree is used to determine 
the risk of infection, with and without the intervention. This risk depends on the baseline risk of 
infection and the reduction in infection risk associated with the intervention, which is represented as 
an odds ratio for the intervention compared to standard of care (SOC). For the illustrative example, 
the only difference between the LIC and MIC is the assessment of health opportunity costs (i.e., cost-
effectiveness threshold) which is $200/DALY for the LIC and $500/DALY for the MIC. The quantities 
used in the model are presented in Table 3.  
 
Table 3: Quantities used in the illustrative model 
Quantity Value 
Probability of infection in low-risk population 0.10 
Probability of infection in high-risk population 0.15 
Effect of intervention on infection risk (odds ratio for intervention compared to SOC) 0.80 
Cost of intervention per individual  $15 
Discounted total cost per infected individual $ 150 
Discounted total DALYs per infected individual 1 
 
The implications of resolving uncertainty is explored in three quantities: (i) the probability of 
infection in low-risk individuals; (ii) the probability of infection in high-risk individuals; and (iii) the 
effect of the intervention on the risk of infection. Uncertainty about each quantity is characterised as 
the probability that the quantity may take different values given the current level of evidence, which 
is formulated as a probability distribution (see Section 4). Uncertainty around the odds ratio (OR) is 
assigned a log-normal distribution (mean OR on natural scale: 0.80 with 95% CI: 0.61, 1.05) and 
uncertainty around the annual probability of infection in the low- and high-risk group is assigned a 
beta distribution (low-risk group: 0.10 with 95% CI: 0.04, 0.16; high-risk group: 0.15 with 95% CI: 
0.08, 0.22). 
 
The results of the cost-effectiveness analysis comparing the intervention to SOC are presented in 
Table 4. The intervention is only cost-effective in the MIC for the high-risk group, as indicated by the 
incremental cost-effectiveness ratio (ICER) falling below the cost-effectiveness threshold and 
positive net health effect. In the other groups, the health benefits of the intervention are insufficient 
to offset the health opportunity costs imposed by the cost of the intervention.  
 
These results represent the expected cost-effectiveness of the intervention. However, due to 
uncertainties in the evidence base, there is a possibility that the intervention is not in fact cost-
effective in the MIC for the high-risk group, or that the intervention is cost-effective in the LIC or MIC 
low-risk groups. These uncertainties in the decision mean that there is potential value to investing in 
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evidence generation activities to reduce the consequences of uncertainty and improve the likelihood 
that the health-maximising decision is made.  
 
Table 4: Cost-effectiveness results for the illustrative example 
Country Subpopulation Incremental cost 
per individual ($) 
(intervention vs. 
SOC) 
DALYs averted 
per individual  
(intervention 
vs. SOC) 
ICER  
($/DALY) 
Cost-
effectiveness 
threshold 
Net 
health 
effect per 
individual 
(DALYs) 
LIC Low-risk $12.24 0.0184 $667 $200 -0.043 
High-risk $11.06 0.0263 $421 $200 -0.029 
MIC Low-risk $12.24 0.0184 $667 $500 -0.006 
High-risk $11.06 0.0263 $421 $500 0.004 
 
6.2 Theme A: Does research seem potentially worthwhile? 
6.2.1 How can health care decisions be influenced by further evidence generation activities? 
Evidence generation activities offer the potential to influence the decision about whether to 
implement the new intervention or to retain SOC. The benefits of an improved evidence base accrue 
each time a more-informed health care decision is made. Therefore, evaluating the potential 
benefits of an improved evidence base requires information about the prevalence and future 
incidence of individuals for whom the evidence could improve decision-making. It also requires a 
judgement about the time horizon over which the decision that will be informed by the evidence is 
made. For example, if additional evidence is gathered in a clinical area in which the pace of 
innovation and introduction of new technologies is rapid, evidence may have a relatively short shelf-
life  ?ƚŚĞ “ƚĞĐŚŶŽůŽŐǇƚŝŵĞŚŽƌŝǌŽŶ ? ?. ũƵĚŐĞŵĞŶƚŝƐĂůƐŽƌĞƋƵŝƌĞĚĨŽƌƚŚĞ “ŵŽĚĞůƚŝŵĞŚŽƌŝǌŽŶ ?ŽǀĞƌ
which costs and health benefits are accrued.  
 
For simplicity in the illustrative example, a constant stream of incident cases is assumed, i.e., in each 
risk group (LIC low-risk, LIC high-risk, MIC low-risk, and MIC high-risk), 500,000 individuals could 
potentially receive the intervention per year. The intervention is used to treat individuals over a 
maximum of 10 years. An improved evidence base, therefore, offers the potential to inform 20 
million decisions (i.e., whether or not to provide the intervention to an individual to reduce the risk 
of acquiring HIV) across the four populations over ten years (equivalent to 17.6 million discounted 
decisions using an annual discount rate of 3%).  
 
6.2.2 Which quantities contribute to decision uncertainty, could feasibly be researched, and 
what would be the value of improving knowledge in relation to these quantities? 
In this example, the three uncertain quantities could feasibly be considered for additional research. 
The risk of infection could be informed by survey data or an observational cohort study, while the 
relative effect of treatment could be informed by a RCT, or other study design that can provide 
information on relative effectiveness.  
 
The value of evidence generation in each population: Figure 2 shows how the principles outlined in 
Section 4 can be applied to the low-risk populations (LIC and MIC), in order to quantify the health 
effects of resolving uncertainty relating to the odds ratio describing the reduced risk of infection 
associated with the intervention compared to SOC. The top panel shows that costs increase and 
DALYs averted reduce as the odds ratio increases and the intervention becomes less effective 
compared to SOC. Therefore, the incremental net health effect of the intervention compared with 
SOC decreases with increasing values of the odds ratio, as shown in the central panel. Although the 
cost and DALYs averted by the intervention are the same across countries, the net health effect is 
lower in the LIC because the investment in the intervention implies higher health opportunity costs.  
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At the mean value for the odds ratio (0.80), the net health effect of the intervention is negative in 
both the LIC and MIC. This reflects the expected cost-effectiveness results shown in Table 4. For the 
LIC, the odds ratio would have to take a value of 0.54 or less for the intervention to be considered 
cost-effective and the likelihood that the odds ratio takes a value this low is very small (probability 
<0.01). This is shown by the small area to the left of the trigger point in the LIC in the lower panel of 
Figure 2, which can be interpreted as the probability that resolving uncertainty about this quantity 
would result in a change in decision. Weighting the potential health consequences of implementing 
the intervention (as shown in the central panel of Figure 2) by the likelihood that the odds ratio 
takes a value that would support this decision (as shown in the lower panel of Figure 2) results in an 
estimate of 57 potential DALYs averted by removing uncertainty about the effectiveness of the 
intervention. In contrast, for the MIC, if the odds ratio takes a value below the MIC trigger point of 
0.75, the intervention would be considered cost-effective. The probability that the odds ratio will 
take a value that results in the intervention turning out to be cost-effective in the MIC is much 
higher than in the LIC with a probability of 0.34, as shown by the larger area to the left of the MIC 
trigger point in the lower panel. Therefore, resolving uncertainty about the effectiveness of the 
intervention could potentially avert 11,405 DALYs in this group.  
 
Figure 3 shows the corresponding results for the high-risk populations. At the mean value for the 
odds ratio (0.80), the net health effect of the intervention remains negative in the LIC but is now 
positive in the MIC due to the higher absolute risk reduction from the intervention. In both 
countries, the trigger point is closer to the mean than in the low-risk populations (LIC: 0.68; MIC: 
0.83) and the probability that the odds ratio could take a value that would support a change in 
decision is higher (LIC: 0.12; MIC: 0.38).  Therefore, resolving uncertainty about the effectiveness of 
the intervention offers the opportunity to avert more DALYs in the high-risk group (LIC 5,622 DALYs 
averted; MIC 29,233 DALYs averted) compared to the low-risk group. 
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Figure 2: Estimating the value of resolving uncertainty about the effectiveness of the intervention  
compared to standard of care in low-risk subpopulations 
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Figure 3: Estimating the value of resolving uncertainty about the effectiveness of the intervention compared 
to standard of care in high-risk subpopulations 
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Table 5 shows the results of aggregating the DALYs averted within and across subpopulations (see 
Section 3). This suggests that a RCT with the potential to generate improved information about the 
effect of the intervention on infection risk offers the potential to avert 46,317 DALYs globally. The 
DALY loss imposed by local research costs can be estimated by dividing the research costs by the 
local cost-effectiveness threshold. Subtracting these DALYs from the DALYs averted via research 
provides an estimate of the net local DALYs averted (or incurred). Where research offers local value, 
i.e., in the LIC high-risk, MIC low-risk, and MIC high-risk populations, the local net health effect can 
be aggregated to estimate the global net health effect associated with research, which is 45,966 
DALYs averted in this example. It is informative to understand the local health care resources that 
would be required to generate these DALYs directly via service provision (see Section 3). In total, 
approximately $21.3 million would be required to avert the same number of DALYs via direct health 
care financing. This is estimated by multiplying the DALYs averted by the local cost-effectiveness 
thresholds. 
 
The above analysis has assumed that the study needs to be run in each subpopulation in order to 
generate health benefits, i.e. that the evidence is not considered generalisable across 
subpopulations. However, in practice, evidence on relative treatment effects, such as that obtained 
via an RCT, is often considered generalizable between jurisdictions and populations with different 
characteristics [38]. If this is the case, then a decision maker may decide to run the trial in one 
population and utilise the resulting information to inform decisions made within other populations 
[39]. This may ultimately reduce research costs, both locally and for the research funder. To 
maximise the global net health effect of research, the decision maker could look across those 
contexts in which the study delivers local net health benefits and choose to only run the study in the 
group in which the DALYs incurred due to local research costs are lowest, i.e., in the MIC low-risk 
group in this example (note, however, that the decision maker is also likely to factor in their own 
research costs and how these vary across populations). This would reduce the local health forgone 
due to research costs by 215 DALYs (i.e., 125 DALYs in the LIC high-risk group plus 90 DALYs in the 
MIC high-risk group). This would also allow the LIC low-risk group to benefit from the research 
without incurring any research costs, thus increasing the DALYs averted via improved information by 
57 DALYs. The total DALYs averted by research would therefore increase to 46,237 and 
approximately $21.4 million would be required to avert the same number of DALYs via direct health 
care financing. 
 
The same approach can be repeated to understand the value of improving the evidence relating to 
infection risk via additional survey data (Table 6). Data on the risk of HIV acquisition is unlikely to be 
considered generalizable across populations. Therefore, the research study must be run in each 
population in order to generate value in the subpopulation, but the research should only be run in 
subpopulations for which the local net health effect is expected to be positive. The total potential 
DALYs averted by the survey are 8,062 and the equivalent health care resources required to avert 
these DALYs via direct service provision are $4.0 million.  
 
These assessments provide an estimate of the aggregate health benefits of potential evidence 
generation activities taking into account the local opportunity costs of research expenditure. They 
also show how the population health benefits are distributed across different populations and 
countries. In this example, the benefits of both the RCT and survey accrue predominantly in the MIC 
with a comparably low number of DALYs averted by research in the LIC (Table 5 and Table 6).  
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Table 5: Aggregating the value of an RCT comparing the new intervention to standard of care across populations 
Country Sub-population Trigger point Decision 
error 
probability* 
DALYs 
avertable 
via 
improved 
information  
Equivalent 
health care 
expenditure 
($) 
Local 
research 
costs 
Local 
health 
forgone 
due to 
research 
costs 
Net local 
health 
effects(DALYs) 
Net local value 
(equivalent health 
care expenditure, $) 
LIC Low-risk 0.54 0.002 57 $11,348 $20,000 100     -43 -$8,652 
High-risk 0.68 0.124 5,622      $1,124,469 $25,000 125     5,497 $1,099,469 
MIC Low-risk 0.75 0.335 11,405 $5,702,487 $40,000 80 11,325 $5,662,487 
High-risk 0.83 0.384 29,233 $14,616,598 $45,000 90 29,143 $14,571,598 
Total    46,317 $21,454,902 $130,000 395 45,922 $21,324,902 
Total assuming no 
generalisability** 
  46,261 $21,443,554 $110,000 295 45,966 $21,333,554 
Total assuming perfect 
generalisability*** 
  46,317 $21,454,902 $40,000 80 46,237 $21,414,902 
* Probability of quantity lying beyond trigger point; ** The trial will not be run in the LIC low-risk group where local net health effect are negative; *** The trial will be run in the MIC low-risk 
group and the evidence generalised to inform decision-making in all groups. 
 
Table 6: Aggregating the value of a survey of HIV risk across populations 
Country Sub-population Trigger point Decision 
error 
probability* 
DALYs 
avertable 
via 
improved 
information  
Equivalent 
health care 
expenditure 
($) 
Local 
research 
costs 
Local 
health 
forgone 
due to 
research 
costs 
Net local 
health 
effects(DALYs) 
Net local value 
(equivalent health 
care expenditure, $) 
LIC Low-risk 0.26 0.000 0      $0 $5,000 25      -25 -$5,000 
High-risk 0.27 0.001 7      $1,343 $5,000 25      -18 -$3,657 
MIC Low-risk 0.14 0.125 2,742 $1,371,071 $10,000 20 2,722 $1,361,071 
High-risk 0.13 0.335 5,360 $2,680,020 $10,000 20 5,340 $2,670,020 
Total   8,109 $4,052,434 $30,000 90 8,019 $4,022,434 
Total assuming no generalisability**   8,102 $4,051,091 $20,000 40 8,062 $4,031,091 
* Probability of quantity lying beyond trigger point; ** The survey will not be run in the LIC low- or high-risk groups where local net health effect are negative. 
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Accounting for the timing and likelihood of research: The value of evidence will also depend on the 
time it takes for the research to be conducted and report, and the likelihood that it will report. 
Research designs that take a long time to complete and report will have a lower value due to the 
reduced time horizon over which the available evidence can be utilised. Similarly, the less likely a 
study is to report, the lower its expected value. Both the time taken for research to report and the 
likelihood that it reports have approximately proportionate effects on the value of evidence (Figure 
4)1. For example, a study that is considered to have a 80% likelihood of reporting, takes 4 years to 
report, and could inform decision-making up to year 10 would deliver 48% of the value shown in 
Table 5 and Table 6. Incorporating the timing and likelihood of research may fundamentally change 
the value of the research proposal. It may also affect the relative value of alternative uses of 
research expenditure, tilting decisions towards those proposals that are expected to report quickly 
and have a high probability of reporting. Understanding the relationship between the time taken for 
research to report, the likelihood that it will report, and the value of the evidence to future 
populations can also help inform: (1) investments that might make research findings more quickly 
available; (2) the trade-off implicit in the choice of alternative research designs; and (3) identification 
of those areas where, if research is to be undertaken, there must be confidence that it can report 
quickly [33].  
 
 
 
Figure 4: Impact of time taken for research to be conducted and report and the likelihood that  
it will report on the value of the evidence generated 
 
6.2.3 Are future uncertainties likely to impact on the value of evidence generation activities? 
The benefits of further evidence generation activities depend upon the presence of other sources of 
uncertainty: changes in the prices of the alternative interventions and comparators; the emergence 
of new technologies that might make existing ones obsolete or change their cost-effectiveness; and 
other relevant research reporting. The impact of future uncertainties on the value of evidence 
generation activities should be considered carefully when the future uncertain event is likely to 
occur and/or will occur before or soon after the research reports. The qualitative effects of future 
uncertainties are described below. Methods for adjusting the quantitative assessments above for 
the effects of future uncertainties are presented in Appendix A.  
 
                                                          
1 Unless discount rates are very high. 
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Price changes: Changes in price not only influence expected cost-effectiveness but also uncertainty 
and the potential benefits of research to future patients. Price changes have had important 
implications for the investment priorities of HIV programmes and the development of the epidemic. 
For example, prices for antiretroviral therapies dropped markedly in the 2000s in sub-Saharan Africa 
as trade rules were relaxed to allow importation of generic forms of these drugs whilst the drugs 
were within their patent period [40]. A more recent example is the cost of viral load assays which 
have fallen over time as a result of agreements with manufacturers and in response to the volume of 
demand [41]. Price reductions are discussed here as these are more commonly observed.  
 
If an intervention is expected to be cost-effective then a price reduction will generally reduce the 
potential benefits of evidence generation activities, since the cost-effectiveness of the intervention 
will be less uncertain and there may be less to gain from further research. If an intervention is not 
expected to be cost-effective then a reduction in price will generally initially increase the value of 
research until the intervention becomes cost-effective, but then eventually reduce as it becomes 
increasingly likely that at the lower price the intervention would be cost-effective2. The value of 
evidence generation activities will not necessarily fall to zero as price falls to zero if there is a 
possibility that the intervention may cause harm. In this situation, even at a zero price, there may be 
value in better understanding the likelihood and magnitude of that harm.  In the illustrative 
example, a price decrease reduces the value of evidence generation in the MIC high-risk population, 
and potentially increases or decreases the value of evidence generation in the other populations. 
  
Assessing the impact of a price change requires information about when major changes in price are 
expected, how likely the price change is, and some evidence about the anticipated extent of the 
price change. Figure 5 illustrates the implications of a 60% price drop at year 4 with a 50% likelihood 
of occurring. The DALYs averted by both the RCT and the survey increase with the price drop, and 
the distribution of the benefits of evidence generation changes markedly. Without the price change, 
benefits are expected to accrue almost exclusively to the populations in the MIC, however, with the 
price drop the majority of DALYs are averted in the LIC. The price drop means that there is much less 
uncertainty about whether to implement the intervention in the MIC.  Therefore, the benefits of 
research are focused in the LIC.  
 
 
Figure 5: Impact of a future price change on the value of evidence generation activities 
Note: the figure assumes that both research studies will report at year 4 and have a 100% likelihood of reporting.  
                                                          
2 These assessments become more complex when there are three or more interventions, and a geometric assessment may 
be necessary to determine the direction of effect.  
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Entry of new interventions: The entry of a new technology will tend to change the relative cost-
effectiveness of the alternative interventions and influence uncertainty in the choice between the 
interventions. The impact of a new intervention on the value of evidence generation will depend on 
whether the new intervention is expected to be cost-effective, and whether this expected cost-
effectiveness changes at different values of the quantity that will be researched via the evidence 
generation activity (Table 7). If the new intervention is not expected to be cost-effective across 
plausible values for the quantity under consideration then its availability will not impact upon the 
value of the evidence generation activity. In other words, there is no result of the research that 
could result in the new intervention being adopted. If the intervention is not cost-effective on 
expectation but could be at some values of the quantity of interest, then the value of research will 
be increased. This is because under some realisations of uncertainty the new intervention offers the 
potential to generate higher net health effect than current interventions, making the research more 
worthwhile. If the intervention is cost-effective on expectation, and at all values of the quantity of 
interest, then the value of the evidence generation activity will be zero. If the intervention is cost-
effective on expectation, but not at all values of the quantity of interest, then the effect on the value 
of evidence generation activity is not clear and understanding the direction of effect may require 
geometric reasoning or quantitative analysis.  
 
Table 7: Impact of new interventions on the value of evidence generation activities  
New intervention cost-effective 
on expectation 
Decision about new intervention switches at some values of the 
quantity of interest 
No Yes 
No Value of evidence generation activity 
unchanged by entry of new 
intervention 
Value of evidence generation 
activity increased by entry of 
new intervention 
Yes Value of evidence generation is zero. 
 
Value of evidence generation 
activity may increase or 
decrease with entry of new 
intervention.  
 
Other research reporting: Research that is already under way, commissioned, or likely to be 
undertaken is relevant as there is a chance that it will change the estimates of cost-effectiveness and 
resolve some of the current uncertainties. The value of evidence generation activities may be 
reduced if decision uncertainty is likely to be resolved in the near future when other research 
reports3. The impact of ongoing research on the value of the current evidence generation activity is 
difficult to predict as it depends upon how the value of the evidence generation activity would be 
modified by different possible results of the ongoing research. Appendix A shows how this can be 
assessed quantitatively. In practice, in most instances the impact of ongoing research on the value of 
evidence generation activities is likely to be modest unless the ongoing research has very similar 
aims and scope to the evidence generation activity under evaluation.  
 
6.2.4 The degree to which uncertainty is expected to be resolved by the proposed evidence 
generation activities 
No evidence generation activity can hope to resolve all uncertainty about a quantity of interest. 
Uncertainties will remain as any evidence generation activity will have a finite sample size and, 
therefore, when combined with the available prior information will not provide a single definitive 
estimate of the quantity of interest. Uncertainties will also always remain due to the possibility of 
biases and imperfect exchangeability between the study setting and the setting in which the 
research findings are to be implemented.  
                                                          
3 Though it is also possible that accounting for ongoing research could increase the value of the evidence generation 
activity under evaluation.  
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The quantitative summaries above have assumed that the evidence generation activity will resolve 
all uncertainty and, therefore, the results represent an expected upper bound on the value of 
additional research. It is useful to consider the situations in which this may/may not represent a 
good approximation to the value of a new study (Figure 6). If prior information is relatively weak (i.e. 
we are highly uncertain about the quantity of interest) and the study planned is both large and 
expected to provide a reliable estimate of the quantity for the context of interest, then the 
quantitative estimates shown above are likely to represent reasonable approximations to the value 
of the study. If prior information is relatively weak but a smaller, less definitive study is likely to be 
conducted then the estimates presented above will overestimate the value of the evidence 
ŐĞŶĞƌĂƚŝŽŶĂĐƚŝǀŝƚǇ ?dŚŝƐĚŽĞƐŶ ?ƚŵĞĂŶƚŚĂƚƚŚe study would not be worthwhile since a smaller-scale 
cheap study could deliver high value (i.e. a low $/DALY averted). If prior information is strong (i.e. we 
are not particularly uncertain about the quantity of interest) then the estimates above may not 
provide a good approximation to the value of the evidence generation activity. However, in this 
situation the research is unlikely to be worthwhile and evidence generation expenditures should be 
focused elsewhere. Methods are available to estimate the value of evidence generation activities 
with different sample sizes, and recent advances have enabled these calculations to be run using the 
outputs of a PSA [29,42,43] (see Rabideau et al (2017) [44] for an application of these methods in 
the context of the Cost-Effectiveness of Preventing AIDS Complications (CEPAC) HIV model).  
  
 
Figure 6: Impact of prior information and sample size on the value of information 
   
It is also possible to estimate the maximum study sample size that could prove to represent a cost-
effective use of research resources. This can be calculated by using EVPPI estimates to understand 
the maximum value of the research in terms of DALYs averted, alongside information on the fixed 
costs of the study and the costs of enrolling each individual in the study (sometimes referred to as 
the marginal sampling cost of the study) and their health opportunity costs. The maximum sample 
size can be calculated by subtracting the health opportunity costs associated with the fixed research 
costs (e.g. fixed trial costs) from the global net health effect associated with the study, and dividing 
the resulting amount by the health opportunity cost per individual enrolled in the study. This 
maximum sample provides an indication of whether a study design in its current form could 
potentially be of value which requires that the proposed sample size is lower than the maximum 
sample size.   
 
6.2.5 A base case for the value of evidence generation activities  
 “ďĂƐĞĐĂƐĞ ?ĂŶĂůǇƐŝƐŝƐŽĨƚĞŶƉƌĞƐĞŶƚĞĚĨŽƌĂĐŽƐƚ-effectiveness study. This represents a set of 
judgements with respect to the most plausible model structure and input quantity values. A similar 
concept can be applied to estimating the value of evidence generation activities. This involves 
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identifying the most plausible values for the populations who can benefit from the improved 
information, the time horizon over which the evidence will be used to inform decision-making, the 
timing and likelihood of the research, whether any future events are considered to be important, 
and whether there is a need to adjust the value of the evidence generation activity to reflect the 
extent to which it will be able to resolve uncertainty. An example set of base case judgements are 
shown in Table 8 and the corresponding implications for the value of evidence generation activities 
shown in Figure 7. These judgements may be subject to sensitivity analysis to assess the impact of 
alternative plausible judgements on the value of evidence generation.  
 
Table 8: Base case judgements relating to evidence generation activities  
Attribute RCT Survey 
Probability of successful 
completion of research 
80% 60% 
Timing of reporting At year 4 At year 2 
Future uncertainties Price change at year 4: 50% chance of 60% price drop 
Likely reduction in 
uncertainty 
Weak prior information and large 
study planned, use EVPPI 
Weak prior information and large 
study planned, use EVPPI 
 
Figure 7: Value of evidence generation activities based on base case judgements 
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6.3 Theme B: What kind of research would best support decision-making? 
6.3.1 Consider the value of alternative study designs  
Different study designs may allow a comparison of different interventions, and may provide data on 
different biochemical, care-related or economic endpoints. All of these differences in study design 
imply that information will be collected on different quantities, and this data collection may 
profoundly impact both the value of the evidence generation activity and its costs. When more than 
one quantity that informs a decision could be informed by an evidence generation activity, the value 
of the evidence generation activity is not simply the sum of the value of reducing uncertainty around 
each quantity [45]. Instead, it is the value of the combined improved information about the 
quantities. In some cases, this joint value may be much greater than the sum of the individual values. 
This would be the case if the decision only changed when both quantities took extreme values (e.g., 
the decision only changed if a service was found to be both cheaper to provide and offered higher 
adherence rates than expected). It is also possible that the joint value will be much lower than the 
sum of the individual values. This would be the case if the resolution of uncertainty in one of the 
quantities meant that the other quantity had little bearing on the decision. The new study may also 
inform other quantities that might not have been considered in the original model. The same 
considerations apply regardless of whether the study includes an additional intervention arm or 
provides information on additional endpoints. Methods for estimating the value of different 
research designs are described in Appendix B.  
 
6.3.2 Consider the value of alternative programmes of research  
Where multiple studies could be commissioned to inform a decision, different types of research 
programmes can be envisaged which may involve commissioning one study, multiple studies 
simultaneously, a sequential approach, whereby decisions about one or more evidence generation 
activities are only made once the results of earlier studies become available, or a watchful waiting 
approach, whereby a decision maker plans to wait until other uncertainties have resolved before 
deciding which studies to commission.  
 
The value of different research programmes will depend on: (1) the joint value of the information 
across the research programmes, which will not simply be a sum of the value of the individual 
studies; (2) the timing of when different studies will report and the implications of this for the time 
horizon over which these studies are expected to contribute to improved decision-making; and (3) 
whether delaying studies via sequential or watchful waiting approaches can ensure that studies are 
only funded when they are most valuable. In general, different research programmes will imply 
different trade-offs. Figure 8 shows five different research programmes that could be commissioned 
in the context of the illustrative example. This shows that upfront commissioning of the RCT, survey, 
or both studies, allows the benefits of these studies to be realised over 8 years for the survey and 6 
years for the RCT.  Although the sequential studies offer the potential to avoid commissioning a 
second study where it would not be worthwhile, there are opportunity costs associated with 
delaying the initiation and, therefore, reporting of the second study. If the RCT is commissioned first, 
the survey will only inform decision-making over 4 years. Similar trade-offs need to be considered 
when adopting a watchful waiting approach.  
 
Sequential research programmes are anticipated to be most valuable when the first study will report 
quickly and when it is likely that the results of the first study could impact upon the decision about 
whether to conduct the second study. Similarly, a period of watchful waiting prior to commissioning 
research is likely to deliver most value if the uncertain event is expected to occur early and modify 
the decision about whether to commission research. Methods for formally evaluating different 
research programmes are presented in Appendix C.  
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Figure 8: Implications of alternative research designs for the time horizon over which research 
 can inform decision-making 
 
The value of alternative research designs is presented in Table 9 for the illustrative example. The 
preferred research design will depend upon the cost of the RCT and survey, and the opportunity 
costs of the research expenditure. However, some general points are worth noting. The sequential 
design that involves commissioning the survey first is unlikely to be considered a valuable 
proposition. This design reduced the global net health effect delivered by the research, due to the 
delay in reporting from year 4, if the RCT is commissioned now, to year 6 if it is commissioned 
following results of the survey. The design is not accompanied by a reduction in costs, since 
regardless of the survey results, the RCT is almost always commissioned (probability of 
commissioning = 99%) as it remains of high value for almost all possible outcomes of the survey. The 
sequential design, which involves commissioning the RCT first, generates considerably more value 
than ĐŽŵŵŝƐƐŝŽŶŝŶŐƚŚĞZdĂůŽŶĞ ?ďƵƚŽŶůǇƌĞƋƵŝƌĞƐƚŚĞƐƵƌǀĞǇƚŽďĞƌƵŶ ?ĂŶĚŝƚ ?ƐĐŽƐƚƐŝŶĐƵƌƌĞĚ ?
with a probability of 60%. Further consideration of the research costs and the distribution of DALYs 
is likely to be necessary in order to inform decision-making with respect to this research design.  
 
Table 9: Value of alternative research designs and the probability that research will be commissioned 
 
DALYs averted via 
improved 
information 
Equivalent health 
care expenditure 
($) 
Probability RCT 
commissioned 
Probability 
survey 
commissioned 
RCT only  20,827  $9,644,617 100% 0% 
Survey only  3,731  $1,865,417 0% 100% 
Concomitant  24,927  $11,242,156 100% 100% 
Sequential (RCT 1st)*  23,033  $10,436,662 100% 60% 
Sequential (Survey 1st)*  16,555  $7,781,150 99% 100% 
 ?/ƚŝƐŶĞĐĞƐƐĂƌǇƚŽƐƚŝƉƵůĂƚĞĂ “ĚĞĐŝƐŝŽŶƌƵůĞ ?regarding commissioning of the second research phase when evaluating the 
sequential research designs. Here it is assumed that: (1) the survey will only be commissioned if the additional DALYs 
generated would have cost at least $500,000 to generate locally via direct health care financing; and (2) the RCT will only 
be commissioned if the additional DALYs generated would have cost at least $2,000,000 to generate locally. **Analysis 
uses base case settings outlined in Table 8 but assuming no price change.  
0
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6.4 Theme C: Are there additional opportunity costs associated with evidence 
generation? 
The analysis presented above assumes that all policy options are available to decision makers 
(adopt, reject, OIR, AWR). The value of evidence generation activities reflect the added value of 
research assuming that the intervention will not be implemented whilst research is conducted in the 
LIC low-risk, LIC high-risk and MIC low-risk groups, i.e., by comparing the net health effect of an OIR 
policy to those generated by a reject policy. For the MIC high-risk group, the value of evidence 
generation activities reflect the added value of research, assuming that the intervention will be 
implemented whilst research is conducted and then potentially continued or withdrawn, depending 
upon the results of the research, i.e., by comparing the net health effect of an AWR policy to an 
adopt policy. Parallel service implementation and research may be impractical for the reasons 
described previously (e.g., difficulty in recruiting to an RCT once an intervention is widely available, 
ethical concerns, difficulty in withdrawing an intervention when research reports and contamination 
of survey results). If these considerations rule out an AWR policy, then the health implications of not 
implementing a cost-effective technology whilst research takes place needs to be accounted for 
when evaluating the evidence generation activity. 
 
If research prohibits adoption, then the value of the evidence generation activity may be reduced 
markedly. For example, if commissioning the RCT means that the intervention cannot be adopted in 
the MIC high-risk subpopulation until the research reports, then this subpopulation cannot accrue 
the health benefits of adopting the intervention during the 4 years research takes to conduct and 
report (Figure 9). The greater the expected net health effect of the intervention, and the longer a 
study will take to report, the larger the reduction in the value of commissioning the RCT. If RCT 
evidence is considered generalizable, it may be feasible to avoid this loss of health by running the 
study in one of the other subpopulations whilst implementing the service within the MIC high-risk 
group. This would avoid the opportunity costs associated with delaying implementation [39].  
 
When assessing the opportunity costs associated with research policies, it is also important to 
consider the time profile of the net health effect of service investments. For many service 
investments there is an initial high commitment of resources. This may occur due to high upfront 
costs associated with setting up a service (e.g., costs of setting up or reconfiguring facilities, or 
expenditure on equipment). If this is the case, an AWR policy is less advantageous because the initial 
upfront costs may be irrecoverable if the research shows that the service is not cost-effective (i.e., 
sunk upfront costs are incurred). Even if set-up costs are not a major consideration, a common 
pattern with interventions in HIV and other long-term conditions is that the costs of rolling out a 
programme of prevention or treatment occur early, whereas the health benefits for recipients often 
take much longer to accrue. In these instances, the benefits of an OIR policy will be increased if the 
intervention can be given once research reports (i.e., research confirms that the intervention is cost-
effective).  
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Figure 9: Impact of research delaying implementation on the value of evidence generation 
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7. Discussion 
This report sets out a framework for evaluating investments in evidence generation activities by 
international research funders. The methods presented have the potential to be used to inform 
decisions influencing the direction of a huge volume of global health resources. By quantifying the 
health implications of alternative uses of research resources, the framework represents an 
important tool for transparent and accountable decision-making. The framework has been 
illustrated using examples from HIV, although the methods can be applied to any decision relating to 
investments in evidence generation activities in low-, middle- or high-income countries. 
 
The approach takes into account both the potential health benefits in local populations who will 
benefit from the evidence, as well as the health opportunity costs of the required research 
expenditure. The framework shows that the local health effects of investments in evidence 
generation activities are quantifiable and depend crucially on the scale of the populations who stand 
to benefit from improved information, the ability of the research study (or programme) to provide 
information that could change decision-making, and the magnitude of any local research costs. The 
framework also emphasises the need to take account of the health opportunity costs of 
international research expenditure, which will depend on the potential alternative uses for those 
research funds which may include other types of research and depending on the remit of the funder, 
non-research investments competing for the same resources.  
 
In this report, the assessments required are illustrated using a simple didactic example. One feature 
of this example is that the costs and outcomes of individuals treated in each year are assumed to be 
independent of the policy choices in previous or subsequent years. This assumption is likely to be 
applicable for the majority of non-communicable disease settings and some infectious disease 
settings; however, for many infectious disease settings this assumption is not considered tenable 
due to the existence of transmission dynamics which have substantive implications for the impact of 
policy interventions. Where these disease dynamics are important, the impact of improved evidence 
for those treated within a given year will depend upon: (i) when the evidence becomes available (as 
the epidemic changes over time); (ii) whether an OIR or AWR policy was pursued as the initial 
adoption or rejection of an intervention as this may modify the epidemic; and (iii) the policy choice 
made beyond the time horizon over which the research is considered valuable. Due to these 
considerations a more complete consideration of the implications of OIR and AWR policies would 
account for the full policy trajectory within a dynamic model. This would involve modelling three 
periods: (i) the period prior to the research reporting in which the decision to adopt or reject the 
intervention depends on whether an OIR or AWR policy is being evaluated; (ii) the period beyond the 
research reporting during which the decision is revised in light of the evidence generated; and (iii) 
the policy choice expected beyond the period over which the research is anticipated to inform 
decision-making. Further work to demonstrate the implementation of this type of modelling is 
required.  
 
In assessing the value of evidence generation activities, the focus has been placed on quantifying the 
benefits of improved information as a way of better understanding the costs and effects of 
alternative investment choices and, therefore, improving programmatic choices about the 
implementation of services. A second way in which evidence generation activities can generate value 
is by ensuring that budget allocations at the regional, programme, and intervention level are closely 
aligned with the funds required to deliver planned services. The extent to which this will be an 
important source of value will depend upon the way in which decision makers manage funds and 
service delivery in response to cost variances. For example, the value of having more robust 
evidence, particularly in relation to costs, is likely to be higher in a decentralised system with limited 
transferability of funds between geographical areas and services, than in a more centralised system 
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where decision makers have the flexibility to manoeuvre funds in response to unfolding events [46]. 
Further work to develop simple metrics to reflect these considerations when estimating the value of 
evidence generation activities is warranted.  
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Appendix A: Methods for assessing the impact of uncertain future events on the 
value of evidence generation activities  
The implications of future events for the value of evidence generation activities will depend upon 
the extent to which the future events are likely to modify the per-period value of the evidence 
generation activity, when the events are expected to occur and their likelihood of occurring. The 
sections below show how to reflect different types of uncertain event when calculating the per-
period value of the evidence generation activity. If we call the original per-period value of the 
evidence generation activity VOI (no future change) and the value reflecting the future change VOI 
(future change) then the overall value of the evidence generation activity is:  
 ܸܱܫሺ݊݋݂ݑݐݑݎ݁݄ܿܽ݊݃݁ሻ  ? ሺݐሻ ൅ ܸܱܫሺ݊݋݂ݑݐݑݎ݁݄ܿܽ݊݃݁ሻ  ? ሺܶ െ ݐሻ  ? ሺ ? െ ݌ሻ൅ ܸܱܫሺ݂ݑݐݑݎ݁݄ܿܽ݊݃݁ሻ  ? ሺܶ െ ݐሻ  ? ݌ 
 
Where T is the time horizon over which the evidence could potentially inform decision-making, t is 
the time point at which the future change is likely to occur, and p is the probability that the future 
change does occur. Discounting should also be applied appropriately but is not shown here for 
simplicity.  
 
Appendix A.1 Assessing the impact of a price change 
The impact of a potential future price change can be quantified by modifying the net health effect 
curve to reflect the new price. An example of the implications of a 60% price reduction for the value 
of an RCT in the LIC high-risk population is shown in Figure 10. The price reduction results in the 
intervention becoming cost-effective on expectation, increases the trigger point value for the odds 
ratio at which the decision would change from 0.68 to 0.88, increases the error probability from 
0.124 to 0.248, and the health benefits of the RCT (from 5,622 DALYs averted to 22,724 DALYs 
averted). The future price change is also uncertain in that it may or may not occur. Therefore, the 
value of evidence generation, with and without the price change, should be weighted to reflect a 
judgement about the likelihood that the price change will and will not occur.  
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Figure 10: Impact of price change on value of evidence generation: value of RCT 
 in LIC high-risk population  
 
Appendix A.2 Assessing the impact of the entrance of a new technology  
The impact of the entrance of a new technology can be quantified by understanding the net health 
effect curve for the new technology and how it changes with the quantity of interest. An example of 
the implications of a new technology for the value of an RCT (comparing the original intervention 
under evaluation to SOC) is shown in Figure 11 for the MIC low-risk population. The new comparator 
is expected to be cost-effective as indicated by the positive net health effect at the mean value of 
the quantity. The trigger point is shifted left from 0.75 to 0.69 since the original intervention has to 
be even more effective to offer a higher net health effect than the new technology, the error 
probability reduces from 0.34 to 0.14, and the health benefits of the RCT also reduce from 11,405 
DALYs averted to 3,583 DALYs averted. Again, if the entry of the new technology is uncertain, the 
value of evidence generation, with and without the new entrant, should be calculated and weighted 
to reflect a judgement about the likelihood that the new entrant will become a viable programmatic 
choice. This shows that innovation can reduce the probability that an innovation will be cost-
effective and, therefore, reduce the value of further research on this comparator. This illustration 
also demonstrates that if the new intervention is currently a relevant comparator it should be 
included when estimating the value of the evidence generation activity. Omission of relevant 
comparators will bias estimates of the value of further research.  
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Figure 11: Impact of new technology on value of evidence generation: value of RCT  
in MIC low-risk population  
 
Appendix A.3 Assessing the impact of ongoing research   
It is slightly more challenging to quantify the implications of other ongoing research reporting for the 
value of an evidence generation activity. This requires computation of the value of the evidence 
generation activity of interest for each possible outcome of the ongoing research. For example, 
consider the implications of improved evidence on the DALYs associated with infection (due to 
improved morbidity or mortality data) for the value of the RCT in the MIC low-risk population. The 
value of the RCT can be estimated using the methods described in the main text but varying the 
DALYs associated with infection across the plausible range for this quantity (i.e., the range of DALY 
values we anticipate that the ongoing research could feasibly generate). This can be used to 
generate the upper panel of Figure 12. This panel shows that the value of the RCT increases as the 
DALYs per infection increases up to approximately 1.40 DALYs lost per infection and then decreases 
beyond this point. As the DALYs lost through infection increase, the decision about implementing the 
intervention becomes more uncertain, and so the value of understanding intervention effectiveness 
via the RCT increases. Eventually, when the DALYs lost through infection become very high, it 
becomes less likely that the RCT will produce a result that would not support implementation of the 
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the ongoing research will be, the value of the RCT as shown in the upper panel of Figure 12 needs to 
be weighted to reflect the likelihood of different results from the ongoing research, as shown by the 
probability distribution in the lower panel of Figure 12. The DALYs averted by the RCT once ongoing 
research is accounted for are 12,669 compared to 11,405 in the absence of additional information 
on DALYs due to infection. The difference between these values is driven by the non-linearity in the 
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curve shown in the upper panel of Figure 12. If this curve is broadly linear, then the ongoing research 
will only have a small impact on the value of the evidence generation activity, as seen here.  
 
 
 
Figure 12: Impact of ongoing research on value of evidence generation: value of RCT 
 in MIC low-risk population  
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Appendix B: Methods for assessing the value of alternative research designs  
Many evidence generation activities could be designed to collect data on one, two or more 
quantities. The choice of which data to collect has implications for research design, the value of the 
research, and the costs of research.  
 
To estimate the value of these alternative designs, the process described in Section 3 can be 
expanded to consider the value of improved information on multiple quantities. If we consider two 
quantities, then this requires an estimate of the net health effect of each intervention conditional 
upon combinations of feasible values of both quantities. The trigger point now becomes a trigger 
boundary, i.e., a set of combinations of the quantities at which the decision would change from the 
decision selected at the mean value of each parameter. The value of a decision change can then be 
weighted by the joint likelihood of both quantities taking values beyond the trigger boundary.  
 
This can be illustrated by considering a three-arm trial which can inform two quantities in the model: 
the relative effectiveness of two of the comparators, each compared to a single comparator that is 
ĐŽŶƐŝĚĞƌĞĚƚŽƌĞƉƌĞƐĞŶƚƚŚĞ “ďĂƐĞůŝŶĞ ?ŝŶƚĞƌǀĞŶƚŝŽŶ ?&ŽƌƚŚĞƉƵƌƉŽƐĞƐŽĨƚŚŝƐŝůůƵƐƚƌĂƚŝŽŶ ?ǁĞĞǆƚĞŶĚ
the calculations above to a situation in which there is a third comparator (new intervention) which is 
cheaper ($5 per treated individual) but less effective than the original intervention considered (odds 
ƌĂƚŝŽĨŽƌŝŶƚĞƌǀĞŶƚŝŽŶ ?ĐŽŵƉĂƌĞĚƚŽ^K P ? ? ? ? ? ? ?A?/ P ?  ? ? ? ? ? ? ? ? ? ?dŚŝƐĐŽŵƉĂƌĂƚŽƌŝƐƚŚĞ “ŶĞǁ
interventŝŽŶ ?ŝůůƵƐƚƌĂƚĞĚŝŶFigure 11 and is cost-effective on expectation. The value of the RCT in this 
context will therefore be realised if it provides estimates of effectiveness that suggest that the new 
intervention is not cost-effective, and that the original intervention or standard of care is cost-
effective. This is shown in the upper panel of Figure 13. The outlined cell shows that at the expected 
value of the two quantities the new intervention has the highest net health effect. At points beyond 
the trigger boundary (shown by the dashed line) the decision switches either to the original 
intervention or to SOC depending on the results of the research. The value of improved information 
is calculated by weighting the gain in net health effect associated with the change in decision by its 
likelihood. For example, if the trial result found an odds ratio of 0.60 for the intervention and 0.80 
for the new intervention the decision would switch to the original intervention. This would result in a 
gain in net health effect per individual of 0.010 DALYs averted (0.024 minus 0.014) which would be 
weighted by the probability of this outcome, which as shown in the lower panel of Figure 13 is 0.004 
(0.013 multiplied by 0.0293). 
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  Effectiveness of new intervention 
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  Net health effect of new intervention 
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0.032 New New New Int Int Int Int Int Int Int Int Int Int Int Int Int Int 
0.60 0.024 New New New New Int Int Int Int Int Int Int Int Int Int Int Int Int 
0.65 0.016 New New New New New Int Int Int Int Int Int Int Int Int Int Int Int 
0.70 0.009 New New New New New New Int Int Int Int Int Int Int Int Int Int Int 
0.75 0.001 New New New New New New New Int Int Int Int Int Int Int Int Int Int 
0.80 -0.006 New New New New New New New SOC SOC SOC SOC SOC SOC SOC SOC SOC SOC 
0.85 -0.013 New New New New New New New SOC SOC SOC SOC SOC SOC SOC SOC SOC SOC 
0.90 -0.021 New New New New New New New SOC SOC SOC SOC SOC SOC SOC SOC SOC SOC 
0.95 -0.028 New New New New New New New SOC SOC SOC SOC SOC SOC SOC SOC SOC SOC 
1.00 -0.035 New New New New New New New SOC SOC SOC SOC SOC SOC SOC SOC SOC SOC 
1.05 -0.042 New New New New New New New SOC SOC SOC SOC SOC SOC SOC SOC SOC SOC 
1.10 -0.048 New New New New New New New SOC SOC SOC SOC SOC SOC SOC SOC SOC SOC 
1.15 -0.055 New New New New New New New SOC SOC SOC SOC SOC SOC SOC SOC SOC SOC 
1.20 -0.062 New New New New New New New SOC SOC SOC SOC SOC SOC SOC SOC SOC SOC 
1.25 -0.068 New New New New New New New SOC SOC SOC SOC SOC SOC SOC SOC SOC SOC 
1.30 -0.075 New New New New New New New SOC SOC SOC SOC SOC SOC SOC SOC SOC SOC 
1.35 -0.081 New New New New New New New SOC SOC SOC SOC SOC SOC SOC SOC SOC SOC 
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Effectiveness of new intervention 
 
 
  
0.55 0.60 0.65 0.70 0.75 0.80 0.85 0.90 0.95 1.00 1.05 1.10 1.15 1.20 1.25 1.30 1.35 
 
 
  Probability quantity takes this value 
 
 
  
0.000 0.000 0.000 0.000 0.024 0.293 0.504 0.166 0.013 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
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0.002 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
0.60 0.013 0.000 0.000 0.000 0.000 0.000 0.004 0.007 0.002 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
0.65 0.054 0.000 0.000 0.000 0.000 0.001 0.016 0.027 0.009 0.001 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
0.70 0.128 0.000 0.000 0.000 0.000 0.003 0.037 0.065 0.021 0.002 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
0.75 0.195 0.000 0.000 0.000 0.000 0.005 0.057 0.099 0.032 0.002 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
0.80 0.211 0.000 0.000 0.000 0.000 0.005 0.062 0.107 0.035 0.003 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
0.85 0.173 0.000 0.000 0.000 0.000 0.004 0.051 0.087 0.029 0.002 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
0.90 0.113 0.000 0.000 0.000 0.000 0.003 0.033 0.057 0.019 0.001 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
0.95 0.062 0.000 0.000 0.000 0.000 0.001 0.018 0.031 0.010 0.001 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
1.00 0.029 0.000 0.000 0.000 0.000 0.001 0.009 0.015 0.005 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
1.05 0.012 0.000 0.000 0.000 0.000 0.000 0.004 0.006 0.002 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
1.10 0.005 0.000 0.000 0.000 0.000 0.000 0.001 0.002 0.001 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
1.15 0.002 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
1.20 0.001 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
1.25 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
1.30 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
1.35 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 
 
Figure 13: Evaluating a three-arm research design: (a) Choice of intervention according to effectiveness of both interventions;  
and (b) probability of different trial results 
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This example raises the wider question of the value of RCT designs with different permutations of 
study arms. The main text focuses on comparing the intervention to SOC, and shows how this can be 
extended to the three-arm trial cases. However, it is also appropriate to consider the value of a trial 
comparing the new intervention to SOC, and a trial comparing the original intervention to the new 
intervention (i.e., there are four possible comparator sets for the RCT). The methods described in the 
main text can be applied to evaluate an RCT comparing the new intervention to SOC. A trial 
comparing the new intervention to the existing intervention will generate improved information on 
the odds ratio comparing the new intervention to the original intervention. Resolving the 
uncertainty around this quantity will reduce the uncertainty around the two quantities in the model 
(the odds ratios comparing the original intervention and new intervention to SOC) but it will not 
resolve it completely. To estimate the value of resolving this uncertainty, we require an estimate of 
the net health effect of the original and new intervention for each plausible value of the odds ratio 
comparing the new intervention to the original intervention. We propose that this is calculated by 
inputting the expected mean of the odds ratios comparing the intervention to SOC and the new 
intervention to SOC conditional upon the odds ratio comparing the new intervention to the original 
intervention. These expected means can be calculated by assuming multivariate normality on the 
log-odds ratio (LOR) scale. The computations are as follows replacing new intervention with the label 
Y and the original intervention with the label X:  
 ܧሺܮܱܴ௑௩௦Ǥௌை஼ȁܮܱܴ௑௩௦Ǥ௒ ൌ ݈݋ݎ௑௩௦Ǥ௒ሻ ൌ ܧሺܮܱܴ௑௩௦Ǥௌை஼ ሻ ൅ ܿ݋ݒሺܮܱܴ௑௩௦Ǥௌை஼ ǡ ܮܱܴ௑௩௦Ǥ௒ሻݒܽݎሺܮܱܴ௑௩௦Ǥ௒ሻ ሺ݈݋ݎ௑௩௦Ǥ௒ െ ܧሺܮܱܴ௑௩௦Ǥ௒ሻሻ ܧሺܮܱܴ௒௩௦Ǥௌை஼ȁܮܱܴ௑௩௦Ǥ௒ ൌ ݈݋ݎ௑௩௦Ǥ௒ሻ ൌ ܧሺܮܱܴ௒௩௦Ǥௌை஼ሻ ൅ ܿ݋ݒሺܮܱܴ௒௩௦Ǥௌை஼ ǡ ܮܱܴ௑௩௦Ǥ௒ሻݒܽݎሺܮܱܴ௑௩௦Ǥ௒ሻ ሺ݈݋ݎ௑௩௦Ǥ௒ െ ܧሺܮܱܴ௑௩௦Ǥ௒ሻሻ 
 
Where the treatment effect estimates have been obtained from a mixed treatment comparison or 
network meta-analysis, the required covariances can be obtained directly from that analysis. Where 
the treatment effect estimates have been obtained from individual trials the covariances are: 
 ܿ݋ݒሺܮܱܴ௑௩௦Ǥௌை஼ ǡ ܮܱܴ௑௩௦Ǥ௒ሻ ൌ ݒܽݎሺܮܱܴ௑௩௦Ǥௌை஼ሻ ܿ݋ݒሺܮܱܴ௒௩௦Ǥௌை஼ ǡ ܮܱܴ௑௩௦Ǥ௒ሻ ൌ െݒܽݎሺܮܱܴ௒௩௦Ǥௌை஼ሻ 
 
These estimates can then be plugged in for each value of the odds ratio comparing the new 
intervention to the original intervention in order to calculate the net health effect of each 
intervention.  
 
When there are more than two quantities of interest the problem becomes more difficult to 
visualise but a similar process can be adopted as shown in Table 10. We assume here that the new 
intervention is cost-effective on expectation. In order to calculate the value of the evidence 
generation activity the values in column [G] are weighted by the probability that quantities 1-3 will 
take the values in columns [A-C] i.e. the probability in column [D]. 
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Table 10: Extending the valuation of evidence generation activities to designs that will inform three or more quantities that are key for decision-making  
Quantity 1 
[A] 
Quantity 2 
[B] 
Quantity 3 
[C] 
Joint probability of 
quantities taking 
values [D] 
Incremental net health effect of 
new intervention conditional 
upon values of quantities 1-3  
[E] 
Incremental net health effect of 
original intervention conditional 
upon values of quantities 1-3 
[F] 
Value of improved 
information 
[G] 
1 1 1 0.01 0.03 0.00 0.00 
1 1 2 0.02 0.03 0.02 0.00 
1 1 3 0.01 0.03 0.05 0.02 
1 2 1 0.02 0.05 0.02 0.00 
1 2 2 0.03 0.05 0.04 0.00 
. . . . . . . 
. . . . . . . 
10 5 3 0.01 0.08 0.09 0.01 
Setting research priorities in Global Health  47 
 
 
Appendix C: Methods for comparing research programmes that include multiple 
evidence generation activities 
Where multiple studies could be commissioned to inform a decision, different types of research 
programmes can be evaluated. In order to evaluate a programme of multiple research studies, the 
joint benefits of the different types of evidence that will be generated need to be estimated. For 
example, in order to evaluate the value of the concomitant programme shown in Figure 8, the value 
of having survey information alone for years 2-4 would need to be added to the value of having both 
survey and RCT data from years 4-10 (with appropriate discounting). The value of having both survey 
and RCT data can be calculated using the methods described in Appendix B. Although this focuses on 
the value of a single study containing multiple quantities, exactly the same principles apply to 
multiple studies collecting data on one or more quantities. The options available to decision makers 
are actually somewhat broader than the summary shown in Figure 8. The concomitant design could 
comprise a decision maker running the RCT (the results of which are considered to generalise across 
populations) and a survey in one, two, three or all four of the populations. The concomitant design, 
therefore, actually comprises 20 alternative designs. As the value of the survey in each 
subpopulation is independent of whether surveys have been conducted in other subpopulations, 
there is no need to consider the value of each design separately. Instead, the additional local net 
health effect of having RCT and survey data (compared to having RCT data alone) in each 
subpopulation can be assessed, and compared to the opportunity costs of the additional 
international research funds required to extend the survey to that population. If the local net health 
effect outweighs the health opportunity costs of the international research funds for a specific 
subpopulation, then the subpopulation should be included within the survey.  
 
For sequential research designs, such as those outlined in Figure 8, additional analyses are required.  
We first consider a sequential design whereby the RCT is commissioned first, and then depending on 
the results of the RCT a decision is made with respect to whether to commission the survey. From 
years 4-6 the value of improved evidence from the RCT only is accrued. For years 6-10 the additional 
expected value and costs of the survey must be considered, taking into account the fact that for 
some results of the RCT the survey will not be considered worthwhile in some or all of the 
populations. This process is shown in Figure 14. For each plausible result of the RCT (simplified here 
to three possible results), the local net health effect are estimated. The total value of the survey 
across populations can then be calculated by aggregating local net health effect where these are 
positive (as in the main text we assume that the survey would not be conducted where it would 
impose net health loss). An assessment is then made as to whether the net DALYs averted are 
sufficient to offset the opportunity costs of the international research funds. When the RCT results 
are such that the the global net DALYs averted by the survey exceed the health opportunity costs of 
the international research funds, the survey is commissioned and its value accrued.  For RCT results 
where this is not the case the survey is not commissioned and no value (or costs) accrue. The 
resulting values can then be weighted to reflect the likelihood of different RCT results and, 
therefore, the expected additional value of the survey.  
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Figure 14: Estimating the value of sequential research designs: RCT followed by survey 
Note: For simplicity, this schematic assumes that the international research funding is the same regardless of the 
subpopulations included in the survey. More complex cost functions can, however, be accommodated by the approach.  
 
If there is a possibility that the RCT will not report, some assumptions need to be made about what 
would happen to the commissioning of the survey in this instance. For example, it may be 
reasonable to assume that the survey decision would be made based on currently available evidence 
on the relative effectiveness of the intervention. In this case, the value from years 4-10 would reflect 
the value of the sequential design, weighted to reflect the likelihood that the RCT does report, and 
the value of conducting the survey (assuming it has a positive net value taking into account the 
opportunity costs of international research funds) weighted to reflect the likelihood that the RCT 
does not report.  
 
For a sequential design, whereby the survey is commissioned first and depending on the results of 
the survey a decision is made with respect to whether to commission the RCT, the process is 
outlined in Figure 15. Again, there are potentially a large number of sequential strategies as the 
survey could be run in one, two, three or all four populations, and the value of the subsequent RCT 
will depend upon the where the surveys were conducted. A pragmatic approach to this issue is to 
assume that decisions about where to run the surveys could be based on the value of the survey 
independent of the RCT. This will provide information on the value of this research programme, 
though may mean that another research programme that provided more value is missed. The main 
differences compared to Figure 14 are that the results of the survey are independent across 
populations, so each survey result actually represents a joint set of survey results across populations. 
A second difference is that due to the generalisability of the RCT evidence, the RCT need only be run 
in the population in which it imposes the lowest DALY opportunity cost.  
Net local DALYs averted by survey
RCT result 1 RCT result 2 RCT result 3
LIC low risk -1000 -800 50
LIC high risk -500 -50 100
MIC low risk 50 2,000 3,000
MIC high risk 100 4,000 5,000
Total DALYs averted 150 6,000 8,150
Effect of  
intervention on infection
1. Results of  RCT at year 4
2. Evaluate net additional local value of  survey over years 6-10 given RCT 
result
4. Assess whether survey offers value taking in to account opportunity 
cost of  international research funds 
RCT result 1 RCT result 2 RCT result 3
Total DALYs averted 150 6,000 8,150
Opportunity cost of 
international funds 
(DALYs)
2,000 2,000 2,000
Net value accrued 0 5,000 6,150
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The same principles can be used to evaluate a watchful waiting strategy, but instead of an initial 
research phase there is a costless evidence generation process which provides information on the 
occurrence and nature of future uncertain events.  
 
 
Figure 15: Estimating the value of sequential research designs: survey followed by RCT 
 
 
 
Prevalence for high and 
low risk groups
1. Results of  surveys at year 2
2. Evaluate net additional local value of  RCT over years 6-10 given survey 
results
4. Assess whether RCT offers value taking in to account opportunity cost 
of international research funds 
Expected value of  RCT = 31,607
DALYs averted by RCT Local DALY cost 
of RCTSurvey results 1 Survey results 2 Survey results 3
LIC low risk 10 50 1,000 100
LIC high risk 5,000 1,000 1,000 125
MIC low risk 15,000 5,000 10,000 80
MIC high risk 25,000 30,000 20,000 90
Total DALYs
averted 44,390 35,970 31,920
DALYs averted Survey results 1 Survey results 2 Survey results 3
Total DALYs averted 44,390 35,970 31,920
Opportunity cost of 
international funds 
(DALYs)
6,000 6,000 6,000
Net value accrued 38,930 29,970 25,920
